Navigation Links
Heyltex Corporation Working With United States and Japan to Add Production of Radiological Antidotes
Date:3/25/2011

KATY, Texas, March 25, 2011 /PRNewswire-USNewswire/ -- Heyltex Corporation is the exclusive U.S. distributor of Radiogardase® (Prussian Blue insoluble capsules), the only FDA-approved drug to treat people who have been internally contaminated with radioactive cesium (Cs-137), which is manufactured by Heyl chem. pharm. Fabrik Berlin GmbH in Germany.

Radiogardase® traps radioactive cesium and thallium in the intestines and keeps them from being re-absorbed by the body. Once Cs-137 has entered the body, it goes through a long rotation of re-absorption within the circulatory system. The ingested Cs-137 is reabsorbed almost completely from the gastrointestinal tract, and, via the bloodstream, is transported to the liver where it enters the gall bladder and is finally returned to the intestine. From the intestine, around 90% is again reabsorbed into the bloodstream and the enterohepatic circulation starts anew. Radiogardase® interrupts this enterohepatic absorption of Cs-137 by knocking this cyclic path out of the gastrointestinal tract and sending it out through the feces.

Heyl chem. pharm. Fabrik GmbH is stepping up production of Radiogardase® to help relieve domestic and global demand.

During nuclear incidents, such as the ongoing emergency at the Fukushima Daiichi Nuclear Power Facility, radioactive material can escape from fuel rods because of heating and consequent cracks in the metal rods. A break in the containment structure, because of explosions or damage from other causes, can permit the radioactive material such as Cs-137 to escape to the environment. The released radioactive material can be inhaled, swallowed with contaminated food or water, or enter the body through open wounds.

Drugs that help to remove this radioactive material from the body are called decorporation drugs. Perhaps best known to the general public is potassium iodide (chemically abbreviated KI). This drug helps keep radioactive iodine from being taken up by the thyroid gland and promotes its excretion. However, there are numerous other decorporation drugs that have been used for many years for accidents involving radiation workers, and rarely, members of the public. Radiogardase® (Prussian Blue insoluble capsules) helps promote the excretion of radioactive cesium, and sodium and calcium diethylenetriamine pentaacetic acid (DTPA) promotes the excretion of radioactive plutonium.

According to Carol Marcus Ph.D., M.D. Professor of Radiation Oncology and of Radiological Sciences, David Geffen School of Medicine, UCLA "The strategic key to emergency preparedness is to stockpile decorporation drugs in advance. Many decorporation drugs have little or no other medical uses, and are not generally kept in pharmacies and hospitals." Dr. Marcus added, "The companies that manufacture these limited use drugs are consequently small, and have little or no surge capacity to ramp up manufacturing if large quantities are needed. By stockpiling drugs ahead of time, as is done in the United States, we will have a ready supply if they are needed."

"The need for these products to be forward deployed around the world is clear," said Alexander Heyl, CEO of Heyltex Corporation. "Radiogardase is an important part of protecting Americans living near nuclear facilities and a key antidote in protecting against a 'Dirty Bomb' attack involving Cs-137." In addition Mr. Heyl stated that, "The unfortunate incident at Fukushima Daiichi Nuclear Power Facility has put the dangers of radiation exposure on the front page and brought into focus the need for continued planning worldwide."

For more information, visit www.heyltex.com.  


'/>"/>
SOURCE Heyltex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
Breaking Medicine News(10 mins):